Ivan Kairatov brings a biopharma lens to one of the most sensitive decisions in pediatrics: when to give the first hepatitis B vaccine. With a research-and-development background rooted in tech and innovation, he translates probabilistic modeling, clinical epidemiology, and practical workflows into
Colorectal cancer remains a top killer, yet traditional screening pathways leave many behind. Clinic-based outreach depends on staffed phone banks, open appointment slots, and patients’ ability to take time off, travel, and navigate insurance rules. In safety-net settings, those frictions stack.
For adults carrying excess weight who are urged to “move more” yet face pain, low fitness, or limited mobility, the search for an exercise approach that is safe, approachable, and still effective can feel like an unsolved puzzle with too many missing pieces and too few realistic options. That
Long after scales celebrate a hard-won weight loss, the immune system can keep score in subtler ways, storing traces of past obesity inside helper T cells as molecular marks that linger and continue to shape health in the background. This emerging insight reframes obesity as more than excess fat;
Clinic days often hinge on one question patients ask with a mix of hope and hesitation: is there a pill that can match the clearing power of injections without the needles, the storage hassles, or the crowded appointment calendar. That answer just shifted as the FDA cleared Johnson & Johnson’s
Ivan Kairatov brings a biopharma lens to clinician-AI collaboration, blending R&D rigor with practical know‑how from tech-enabled trials. In recent studies, chatbots not only matched but sometimes outperformed clinicians on management reasoning tasks, especially when teams used deliberate workflows
